조병철 (연세대학교 의과대학)님 | 한빛사연구자 > 한빛사

연세대학교 의과대학

CV File

종양의학

최종업데이트 2025.09.11.

- 조병철(연세대학교 의과대학)
Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial
- J. Thorac. Oncol., Sep 09 2025, S1556-0864(25)00939-6 | https://doi.org/10.1016/j.jtho.2025.07.117
- 2025-09
- 의약학
- 한빛사논문
- 조병철(연세대학교 의과대학)
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
- N. Engl. J. Med., Published September 6, 2025 | DOI: 10.1056/NEJMoa2503001
- 2025-09
- 의약학
- 한빛사논문
Evolving roles of MET as a therapeutic target in NSCLC and beyond
- Nat. Rev. Clin. Oncol., Published: 18 July 2025 | https://doi.org/10.1038/s41571-025-01051-9
- 2025-07
- 의약학
- 한빛사논문
- 조병철(연세대학교 의과대학)
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
- Nat. Med., Apr 29 2025, | https://doi.org/10.1038/s41591-025-03688-6
- 2025-04
- 의약학
- 한빛사논문
- 조병철(연세대학교 의과대학)
Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A
- J. Thorac. Oncol., Jan 02 2025, S1556-0864(24)02550-4 | https://doi.org/10.1016/j.jtho.2024.12.029
- 2025-01
- 의약학
- 한빛사논문
- 조병철(연세대학교 의과대학)
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
- N. Engl. J. Med., Jun 26 2024, | https://doi.org/10.1056/NEJMoa2403614
- 2024-06
- 의약학
- 한빛사논문
D3S-001, a KRAS G12C inhibitor with rapid target engagement kinetics, overcomes nucleotide cycling and demonstrates robust preclinical and clinical activities
- Cancer Discov., May 08 2024, | https://doi.org/10.1158/2159-8290.CD-24-0006
- 2024-05
- 의약학
- 한빛사논문
Discovery of a novel potent EGFR inhibitor against EGFR activating mutations and on-target resistance in NSCLC
- Clin. Cancer Res., Feb 08 2024, | https://doi.org/10.1158/1078-0432.CCR-23-2951
- 2024-02
- 의약학
- 한빛사논문
- 조병철(연세대학교 의과대학)
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
- N. Engl. J. Med., Jan 11 2024, 390 (2) | https://doi.org/10.1056/NEJMoa2302299
- 2024-01
- 의약학
- 한빛사논문
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
- JAMA Oncol., Sep 28 2023, e233867 | https://doi.org/10.1001/jamaoncol.2023.3867
- 2023-09
- 의약학
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기